Excerpt:
Tracing the central dogma of biology (left column), we can link specific data types (middle column) to explain each of these biological processes. In this work, novel biological regularities that relate these processes are discovered through: (i) primary omics data (top box, right column) and (ii) integration with GEMs (bottom box, right column).
 
Excerpt:
The approach directly addresses the BD2K grand challenge and is made conceptually accessible by tracing the ‘information flow’ through the familiar ‘central dogma’, to establish relationships between measurements and cell physiology (Fig. 1).

My comment: Information flow is energy-dependent and controlled by the physiology of reproduction. That fact links feedback loops from olfaction and pheromones to all biodiversity via polycombic ecological adaptations in the context of autophagy and chromosomal rearrangements. It links virus-driven energy theft from hecatombic evolution and mutations to all pathology.

The focus on biological regularities instead of pseudoscientific nonsense about mutations and evolution links natural selection for codon optimality to energy-dependent healthy longevity via fixation of biophysically constrained RNA-mediated amino acid substitutions in supercoiled DNA, which prevents virus-driven entropy in all organized genomes.Their cotranslationally folded motifs are examples of why polycombic fixation of RNA-mediated amino acid substitutions must be linked from energy-dependent changes in cell types to healthy longevity by two novel regularities: “…condition invariant in vivo turnover rates of enzymes and the correlation of protein structural motifs and translational pausing.”The pausing ensures energy-dependent changes in the structure and function of G protein-coupled receptors that link the epigenetic landscape to the physical landscape of supercoiled DNA in all living genera via the physiology of reproduction.

Darwin addressed the facts about the “…condition invariant in vivo turnover rates…” in the context of his “conditions of life,” which do not vary across species or in the context of transgenerational epigenetic inheritance of morphological and behavioral phenotypes. All conditions of life are energy-dependent and natural selection for energy-dependent codon optimality has since linked energy as information from the sun’s anti-entropic virucidal energy to cell type differentiation via RNA-mediated DNA repair in the context of femotosecond blasts of ultraviolet light.

See: Ultraviolet Absorption Induces Hydrogen-Atom Transfer in G⋅C Watson–Crick DNA Base Pairs in Solution

See also: 

See also: RNA Interference (RNAi) as a Metronome of the Circadian Cadence

See also: Get Well in the RNAi Way-RNAi, A Billion Dollar Baby in Therapy

My comment: If you stay well, you will not need anyone to attempt to fix your genome.

See for example: RNA-Guided Human Genome Engineering

Also, you will be exposed to less risk of failed therapies.

See: Product Development Pipeline

Sad news re first miRNA drug candidate: “MRX34, the first microRNA mimic to enter clinical development in oncology, was studied as a single agent in a multi-center Phase 1 clinical trial, which included patients with primary liver cancer, other solid cancers, and hematological malignancies (lymphomas and leukemias). MRX34 entered clinical testing in 2013. In September 2016, we voluntarily halted enrollment and dosing in the clinical study following multiple immune-related severe adverse events (SAEs) observed in patients dosed with MRX34 over the course of the trial. We are further analyzing our preclinical and clinical data set and are in the process of discussing with our advisors, as well as the Food and Drug Administration, regarding possible future development of MRX34.”

See also: A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Description: This is a Phase I, open-label, multicenter, dose-escalation study to investigate the safety, Pharmacokinetics and Pharmacodynamics of the micro ribonucleic acid (microRNA) MRX34, in patients with unresectable primary liver cancer or advanced or metastatic cancer with or without liver involvement or hematologic malignancies. MRX34 will be administered daily x 5 with 2 weeks off (total of 21 days) for 3 cycles followed by a no-treatment observation period.

Outcome: This study has been terminated. (Five immune related serious adverse events)

See also: Polycombic ecological adaptation as a science, not a theory (2)

Keep Reading